WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525921
CAS#: 853003-48-2
Description: PF-00489791, also known as PF-4634817, is an inhibitor of phosphodiesterase type 5. PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
Hodoodo Cat#: H525921
Name: PF-00489791
CAS#: 853003-48-2
Chemical Formula: C20H28N8O4S
Exact Mass: 476.20
Molecular Weight: 476.560
Elemental Analysis: C, 50.41; H, 5.92; N, 23.51; O, 13.43; S, 6.73
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: PF-00489791; PF 00489791; PF00489791; PF-4634817; PF 4634817; PF4634817.
IUPAC/Chemical Name: 1H-Pyrazolo(4,3-d)pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-((4-methyl-2-pyridinyl)amino)-N-(methylsulfonyl)
InChi Key: ZUHZNKJIJDAJFD-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H28N8O4S/c1-6-27(4)20-23-15-16(19(29)26-33(5,30)31)25-28(10-11-32-7-2)17(15)18(24-20)22-14-12-13(3)8-9-21-14/h8-9,12H,6-7,10-11H2,1-5H3,(H,26,29)(H,21,22,23,24)
SMILES Code: O=C(C1=NN(CCOCC)C2=C(NC3=NC=CC(C)=C3)N=C(N(CC)C)N=C21)NS(=O)(C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 476.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Scheele W, Diamond S, Gale J, Clerin V, Tamimi N, Le V, Walley R, Grover-Páez F, Perros-Huguet C, Rolph T, El Nahas M. Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy. J Am Soc Nephrol. 2016 Apr 25. pii: ASN.2015050473. [Epub ahead of print] PubMed PMID: 27113485.
2: Afsar B, Ortiz A, Covic A, Gaipov A, Esen T, Goldsmith D, Kanbay M. Phosphodiesterase type 5 inhibitors and kidney disease. Int Urol Nephrol. 2015 Sep;47(9):1521-8. doi: 10.1007/s11255-015-1071-4. Epub 2015 Aug 5. Review. PubMed PMID: 26242375.
3: Wolk R, Smith WB, Neutel JM, Rubino J, Xuan D, Mancuso J, Gilbert J, Pressler ML. Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. Hypertension. 2009 Jun;53(6):1091-7. doi: 10.1161/HYPERTENSIONAHA.109.132225. Epub 2009 Apr 27. PubMed PMID: 19398651.
